• Mashup Score: 0

    July 11, 2023 — Hyperfine, Inc., the groundbreaking medical device company that created the Swoop system, the world’s first FDA-cleared portable magnetic resonance brain imaging system, has announced the commencement of an international, multi-site observational study, ACTION PMR (ACuTe Ischemic strOke detectioN with Portable MR). To support its acute stroke care initiatives, Hyperfine Inc. has…

    Tweet Tweets with this article
    • @DAICeditor @Hyperfine Hyperfine announced the commencement of an international, multi-site observational #study, #ACTION_PMR (ACuTe Ischemic strOke detectioN with Portable #MR): https://t.co/Vg0qp3Pj8k

  • Mashup Score: 0

    July 6, 2023 — BIOTRONIK announced U.S. Food and Drug Administration (FDA) approval of its portfolio of Amvia Edge pacemakers and cardiac resynchronization therapy pacemaker (CRT-P), its latest innovation in cardiac rhythm management. Amvia Edge, the market’s smallest single-chamber MR conditional pacemaker1, introduces a unique set of patient-centric clinical solutions coupled with automated…

    Tweet Tweets with this article
    • @DAICeditor @BIOTRONIK_US The #AmviaEdge #pacemaker platform introduces always-on, automatic #MR detection algorithm to fully streamline #MRI #workflow: https://t.co/FqVHEdBsxl #FDA #pacemaker

  • Mashup Score: 0

    July 3, 2023 — According to an accepted manuscript published in ARRS’ own American Journal of Roentgenology (AJR), preferential use of pulmonary MR angiography (MRA) for diagnosing pulmonary embolus (PE) in the general population helped conserve iodinated contrast media during the 2022 shortage.  “This single-center experience demonstrates use of pulmonary MRA as a practical substitute for…

    Tweet Tweets with this article
    • @DAICeditor @ARRS_Radiology Preferential use of pulmonary #MR #angiography (#MRA) for diagnosing #pulmonaryembolus (PE) in the general population helped conserve #iodinated #contrastmedia during the 2022 shortage: https://t.co/yFwUwg3fUb

  • Mashup Score: 1

    In a THT 2023 debate, a 57-year-old with severe HF was the jumping off point for discussing what’s gained or lost with TEER.

    Tweet Tweets with this article
    • #TEER or VAD/Transplant in the Advanced HF Patient With MR? When faced with a patient with advanced #HF and severe #MR, how do you decide whether to first try transcatheter repair or to proceed directly for advanced HF therapies: a #VAD or transplant https://t.co/cESzjNqCKx… https://t.co/R1gHHsZRiS